NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 5.7% - What's Next?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) rose 5.7% during trading on Wednesday . The company traded as high as $21.18 and last traded at $21.17. Approximately 70,164 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 728,111 shares. The stock had previously closed at $20.02.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target for the company. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.89.

NewAmsterdam Pharma Stock Down 2.2%

The business's 50 day moving average is $19.10 and its two-hundred day moving average is $20.37. The firm has a market cap of $2.42 billion, a P/E ratio of -11.46 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper acquired 8,584 shares of NewAmsterdam Pharma stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the completion of the acquisition, the director directly owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This represents a 0.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Douglas F. Kling sold 100,000 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at $848,760. The trade was a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have bought 12,364 shares of company stock valued at $236,839 over the last quarter. Corporate insiders own 20.84% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Quarry LP bought a new position in shares of NewAmsterdam Pharma during the first quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $50,000. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after purchasing an additional 3,390 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.